No Detail Found!

Efficacy of metformin in obese versus non-obese women with polycystic ovary syndrome (PCOS)

Author(s)
Fiza Ali Khan Department of Obstetrics & Gynecology, Dow Medical College, Dr. Ruth K. M. Pfau, Civil Hospital,Karachi,Pakistan
Misbah Mehmood Muhammad Medical College, Mirpurkhas, Pakistan
Samreen Kazmi Zainab Panjwani Memorial Hospital,Karachi,Pakistan
Sehrish Sheraz Dow Institute of Medical Technology, Dow University of Health Sciences,Karachi,Pakistan
Sadia Bhatti Department of Dermatology, Dow University Hospital,Ojha Campus, Karachi,Pakistan
Jawed Akbar Dars Department of Psychiatry and Behavioral Sciences, Jinnah Postgraduate Medical Center,Karachi,Pakistan
Aniqa Saleem Department of Physiology, Sindh Institute of Physical Medicine and Rehabilitation,Karachi,Pakistan
Kiran Abbas Aga Khan University Hospital,Karachi,Pakistan
Abstract
Background:Polycystic Ovary Syndrome (PCOS) is a common cause of amenorrhea and infertility among women. Objective: The study evaluated the eficacy of metformin in obese versus non-obese women with Polycystic Ovary Syndrome (PCOS). Methods:A quasi-experimental study was conducted at a tertiary care center between March 2018 to December 2021. All patients who presented with chronic anovulation with oligomenorrhea or amenorrhea and polycystic ovaries on ultrasound were included in the study. Women with hyperprolactinemia, pregnancy, or lactation were excluded. Non-obese participants were labeled as “Group A” while obese were labeled as “Group B”. Metformin therapy was initiated at an oral dose of 500 mg per day for the first week, followed by two times a day for another week. Ovulation and menstrual regularity were documented after six months of treatment. Metformin was considered efective if menstrual cycles were normalized and ovulation was achieved. Results: The eficacy of metformin was 83.15% in non-obese women while in obese women it was only 53.65% (p<0.001). The ovulation was more frequently achieved by non-obese women as compared to obese women [296 (83.15%) vs. 115 (32.3%); p<0.001]. In lean patients fasting serum insulin reduced from 9.7±3.4 mU/l vs. 6.2±3.8 mU/l, (p=0.032) while in obese patients, it changed from 20.2±10.2 mU/l vs. 14.4±3.2 mU/l (p<0.001). Conclusion: The study concluded that metformin was efective in improving symptoms of PCOS in patients irrespective of the body mass index.
Publication Details
Page(s) 124-128
Published Journal: Liaquat National Journal of Primary Care, Volume: 4, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Obesity, Metformin, Polycystic Ovary Syndrome (PCOS), Ovulation, Amenorrhea, anovulation
0

Citations

0

Downloads

50

Views